Search

Your search keyword '"Balduyck, Malika"' showing total 23 results
Start Over Author "Balduyck, Malika" Search Limiters Available in Library Collection
23 results on '"Balduyck, Malika"'

2. Impact of nutrition route on microaspiration in critically ill patients with shock: a planned ancillary study of the NUTRIREA-2 trial

Author

Nseir, Saad, Le Gouge, Amélie, Lascarrou, Jean-Baptiste, Lacherade, Jean-Claude, Jaillette, Emmanuelle, Mira, Jean-Paul, Mercier, Emmanuelle, Declercq, Pierre-Louis, Sirodot, Michel, Piton, Gaël, Tinturier, François, Coupez, Elisabeth, Gaudry, Stéphane, Djibré, Michel, Thevenin, Didier, Pasco, Jeremy, Balduyck, Malika, Zerimech, Farid, and Reignier, Jean

Published
2019
Full Text
View/download PDF

5. Are Cirrhotic Patients Receiving Invasive Mechanical Ventilation at Risk of Abundant Microaspiration.

Author

Levy, Clementine, Gaudet, Alexandre, Jaillette, Emmanuelle, Reignier, Jean, Lassailly, Guillaume, Balduyck, Malika, Cailliau, Emeline, Rouze, Anahita, and Nseir, Saad

Subjects
ARTIFICIAL respiration, INTENSIVE care units, VENTILATOR-associated pneumonia
Abstract

Previous studies have identified cirrhosis as a risk factor for ventilator-associated pneumonia (VAP). The aim of our study was to determine the relationship between cirrhosis and abundant gastric-content microaspiration in intubated critically ill patients. We performed a matched cohort study using data from three randomized controlled trials on abundant microaspiration in patients under mechanical ventilation. Each cirrhotic patient was matched with three to four controls for gender, age ± 5 years and simplified acute physiology score II (SAPS II) ± 5 points. Abundant microaspiration was defined by significant levels of pepsin and alpha-amylase in >30% of tracheal aspirates. All tracheal aspirates were collected for the first 48 h of the study period. The percentage of patients with abundant gastric-content microaspiration was the primary outcome. The abundant microaspiration of oropharyngeal secretions, VAP incidence, the duration of mechanical ventilation, length of intensive care unit (ICU) stay and mortality were the secondary outcomes. A. total of 39 cirrhotic patients were matched to 138 controls. The percentage of patients with abundant gastric-content microaspiration did not differ between the two groups (relative risk: 0.91 (95% CI: 0.75 to 1.10)). There was no significant difference between the two groups in terms of the abundant microaspiration of oropharyngeal secretions, VAP, the duration of mechanical ventilation, the length of ICU stay and mortality. Our results suggest that cirrhosis is not associated with abundant gastric-content microaspiration. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

6. Additional file 1 of Is COPD associated with increased risk for microaspiration in intubated critically ill patients?

Author

Thècle Degroote, Jaillette, Emmanuelle, Reignier, Jean, Zerimech, Farid, Girault, Christophe, Brunin, Guillaume, Chiche, Arnaud, Lacherade, Jean-Claude, MIRA, Jean-Paul, Maboudou, Patrice, Balduyck, Malika, and Nseir, Saad

Abstract

Additional file 1: Table S1. Risk factors for abundant microaspiration by univariate and multivariate analyses. Table S2. Outcomes of patients, including suspected COPD.

Published
2021
Full Text
View/download PDF

7. How did the private labs fit onto COVID-19 crisis?

Author

Galhaud, Jean-Philippe, Scherrer, Florian, Kemeny, Stephan, Beauvieux, Marie-Christine, Delevallee, Céline, Aimone-Gastin, Isabelle, Alcaraz, Stéphanie, Allouche, Stephane, Balduyck, Malika, Barbe, Françoise, Barguil, Yann, Bastard, Jean Philippe, Beaudeux, Jean-Louis, Ben Lassoued, Amin, Benz-de Bretagne, Isabelle, Bérard, Annie, Bermont, Laurent, Bigot-Corbel, Edith, Bost, Muriel, Bourbonneux, Valery, Brunel, Valéry, Carré, Jean-Luc, Chenevier-Gobeaux, Camille, Chevrier, Marc, Chinetti, Giulia, Collin-Chavagnac, Delphine, Delacour, Hervé, Delevallée, Delphine, Desroys du Roure, François, Faure, Patrice, Galinier, Anne, Hauet, Thierry, Helj, Carine, Jolly, Emilie, Kamel, Saïd, Lehmann, Sylvain, Leroy, Aline, Lessenger, Jean-Marc, Levy, Pacifique, Lorec-Penet, Anne-Marie, Mesli, Samir, Monnet, Dagui, Moreau, Caroline, Mouly-Badina, Laurence, Nivet-Antoine, Valerie, Oueidat, Nathalie, Pecquet, Mathieu, Peoc'h, Katell, Pieroni, Laurence, Poupon, Carole, Roubille, Martine, Rucheton, Benoit, Sakka, Medhi, Sapin, Vincent, Saunier, Vincent, Schmitt, François, Zaepfel, Sabine, Zozor, Samuel, Groupe Labexa, Synlab Vallée du Rhône, Gen-Bio, CHU Bordeaux [Bordeaux], Centre de résonance magnétique des systèmes biologiques (CRMSB), Centre National de la Recherche Scientifique (CNRS)-Université de Bordeaux (UB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), and Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)

Subjects
030213 general clinical medicine, Medical laboratory, Pre-Analytical Phase, MESH: Medical Staff, 0302 clinical medicine, Medical Staff, MESH: COVID-19, Intersectoral Collaboration, MESH: Intersectoral Collaboration, Cross Infection, Equipment Safety, MESH: Clinical Laboratory Services, General Medicine, Clinical Laboratory Services, MESH: Pre-Analytical Phase, 3. Good health, MESH: Patient Safety, Private Sector, Medical emergency, France, Patient Safety, MESH: Private Sector, MESH: Hospital Units, Hospital Units, health crisis, 2019-20 coronavirus outbreak, MESH: Pandemics, private medical laboratories, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), SARS CoV-2, Specimen Handling, 03 medical and health sciences, medicine, Humans, MESH: SARS-CoV-2, MESH: Specimen Handling, Pandemics, MESH: Clinical Laboratory Techniques, MESH: Humans, Health professionals, business.industry, Clinical Laboratory Techniques, SARS-CoV-2, pandemia, Cornerstone, COVID-19, MESH: Cross Infection, Front line, medicine.disease, MESH: Equipment Safety, MESH: France, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; Confronted with the COVID-19 crisis, healthcare professionals have had to tackle an epidemic crisis of a huge magnitude for which they were not prepared. Medical laboratories have been on the front line, from collecting samples to performing the analysis required to diagnose this new pathology. Responding to the needs and to the urgency of the situation, the authorities relied on the network of private laboratories. In France, private laboratory medicine represents 70% of overall activity, and with a network of more than 4,000 local laboratories, private laboratory medicine has been the cornerstone of the « screen-trace-isolate » strategy. This article gives feedback from private laboratory medicine professionals, directly involved in the reorganization carried out at the pre-analytical, analytical and post-analytical stages, during the crisis from March to October 2020.

Published
2020

8. Additional file 1 of Transesophageal echocardiography-associated tracheal microaspiration and ventilator-associated pneumonia in intubated critically ill patients: a multicenter prospective observational study

Author

Bagate, François, Rouzé, Anahita, Zerimech, Farid, Boissier, Florence, Labbe, Vincent, Razazi, Keyvan, Carteaux, Guillaume, Prost, Nicolas De, Balduyck, Malika, Maboudou, Patrice, Nseir, Saad, and Dessap, Armand Mekontso

Subjects
bacterial infections and mycoses, human activities, respiratory tract diseases
Abstract

Additional file 1: Table S1. Microaspiration indicators and outcomes stratified by VAP incidence within 5 days after TEE.

Published
2020
Full Text
View/download PDF

11. Additional file 1: of Description of 22 new alpha-1 antitrypsin genetic variants

Author

CÊline Renoux, Marie-FrançOise Odou, Tosato, Guillaume, Teoli, Jordan, Abbou, Norman, Lombard, Christine, Zerimech, Farid, Porchet, Nicole, Cellier, Colette Chapuis, Balduyck, Malika, and Joly, Philippe

Abstract

Figure S1. A1AT phenotypes: (A) Coomassie blue stained polyacrylamide gel (B) agarose gel followed by immunofixation. 1:M1; 2:M2S; 3:M1M4; 4,5,6: M2P; 7:M2SRoubaix; 8: IM; 9:M2SRoubaix; 10,11:M1Z; 12:M1; 13:M2S; 14:M1S. The SRoubaix variant has clearly different patterns of migration on polyacrylamide and on agarose gels. (PPTX 217 kb)

Published
2018
Full Text
View/download PDF

13. Is COPD associated with increased risk for microaspiration in intubated critically ill patients?

Author

Degroote, Thècle, Jaillette, Emmanuelle, Reignier, Jean, Zerimech, Farid, Girault, Christophe, Brunin, Guillaume, Chiche, Arnaud, Lacherade, Jean-Claude, MIRA, Jean-Paul, Maboudou, Patrice, Balduyck, Malika, Nseir, Saad, for the MicroCOPD study group, Mercier, Emmanuelle, Declercq, Pierre-Louis, Sirodot, Michel, Piton, Gaël, Tinturier, François, Coupez, Elisabeth, and Gaudry, Stéphane

Subjects
CRITICALLY ill, OBSTRUCTIVE lung diseases, ARTIFICIAL respiration, ALPHA-amylase, PEPSIN
Abstract

Background: Although COPD patients are at higher risk for aspiration when breathing spontaneously, no information is available on the risk for microaspiration in invasively ventilated COPD patients. The aim of our study was to determine the relationship between COPD and abundant microaspiration in intubated critically ill patients. Methods: This was a retrospective analysis of prospectively collected data, provided by 3 randomized controlled trials on microaspiration in critically ill patients receiving invasive mechanical ventilation for more than 48 h. Abundant microaspiration was defined as the presence of pepsin and or alpha-amylase at significant levels in tracheal aspirates. In all study patients, pepsin and alpha-amylase were quantitatively measured in all tracheal aspirates collected during a 48-h period. COPD was defined using spirometry criteria. Results: Among the 515 included patients, 70 (14%) had proven COPD. Pepsin and alpha-amylase were quantitatively measured in 3873 and 3764 tracheal aspirates, respectively. No significant difference was found in abundant microaspiration rate between COPD and non-COPD patients (62 of 70 patients (89%) vs 366 of 445 (82%) patients, p = 0.25). Similarly, no significant difference was found in abundant microaspiration of gastric contents (53% vs 45%, p = 0.28), oropharyngeal secretions (71% vs 71%, p = 0.99), or VAP (19% vs 22%, p = 0.65) rates between the two groups. No significant difference was found between COPD and non-COPD patients in duration of mechanical ventilation, ICU length of stay, or ICU mortality. Conclusions: Our results suggest that COPD is not associated with increased risk for abundant microaspiration in intubated critically ill patients. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

15. Tapered-cuff Endotracheal Tube Does Not Prevent Early Postoperative Pneumonia Compared with Spherical-cuff Endotracheal Tube after Major Vascular Surgery

Author

Monsel, Antoine, primary, Lu, Qin, additional, Le Corre, Marine, additional, Brisson, Hélène, additional, Arbelot, Charlotte, additional, Vezinet, Corinne, additional, Fléron, Marie-Hélène, additional, Ibanez-Estève, Christina, additional, Zerimech, Farid, additional, Balduyck, Malika, additional, Dexheimer, Felippe, additional, Wang, Chunyao, additional, Langeron, Olivier, additional, and Rouby, Jean-Jacques, additional

Published
2016
Full Text
View/download PDF

18. Heterozygous M3Mmalton α1-Antitrypsin Deficiency Associated with End-Stage Liver Disease: Case Report and Review

Author

Canva, Valérie, primary, Piotte, Sandrine, primary, Aubert, Jean-Pierre, primary, Porchet, Nicole, primary, Lecomte-Houcke, Martine, primary, Huet, Guillemette, primary, Zenjari, Tahar, primary, Roumilhac, Didier, primary, Pruvot, François-René, primary, Degand, Pierre, primary, Paris, Jean-Claude, primary, and Balduyck, Malika, primary

Published
2001
Full Text
View/download PDF

20. The major human urinary trypsin inhibitor is a proteoglycan.

Author

Balduyck, Malika, Mizon, Charlotte, Loutfi, Hamid, Richet, Colette, Roussel, Philippe, and Mizon, Jacques

Subjects
*TRYPSIN inhibitors, *PROTEOGLYCANS, *GLYCOSAMINOGLYCANS, *ENZYMES, *MANNOSE, *GALACTOSE
Abstract

The major urinary trypsin inhibitor (Mr 44000), isolated from human urine, contains 35% carbohydrate. In addition to N-acetylglucosamine and neutral sugars (primarily mannose and galactose), the carbohydrate moiety contains hexuronic acid and N-acetylgalactosamine and corresponds to a glycosaminoglycan. This carbohydrate chain is an integral component of the inhibitor: it does not dissociate from the inhibitor when using dissociative conditions such as sodium dodecyl sulfate, guanidinium chloride, or by increasing ionic strength or mixing with cetylpyridinium chloride. This glycosaminoglycan chain is sensitive to chondroitinase ABC or testicular hyaluronidase digestion and corresponds to slightly sulfated chondroitin 4-sulfate or 6-sulfate. After treatment by these enzymes, the urinary inhibitor has a lower molecular mass (Mr 26000) but still inhibits trypsin. [ABSTRACT FROM AUTHOR]

Published
1986
Full Text
View/download PDF

21. Chondroitin sulphate covalently cross-links the three polypeptide chains of inter-α-trypsin inhibitor.

Author

Morelle, Willy, Capon, Calliope, Balduyck, Malika, Sautiere, Pierre, Kouach, Mostapha, Michalski, Catheine, Fournet, Bernard, and Mizon, Jacques

Subjects
PROTEINS, TRYPSIN inhibitors, ENZYME inhibitors, GROWTH factors, PEPTIDE hormones, BIOCHEMISTRY
Abstract

Inter-α-trypsin inhibitor (ITI) is a tight complex of three different proteins: bikunin and two heavy chains H1 and H2. In order to demonstrate that the three chains are covalently linked by a chondroitin sulphate chain as previously proposed [Enghild. J. J., Salvesen, G., Hefta. S. A., Thoger sen. I. B., Rutherford. S. and Pizzo. S. V. (1991) J. Biol. Chem. 266, 747-751], ITI was extensively digested with thermolysin and the glycosaminoglycan-containing fragment was isolated from the digest by ion-exchange chromatography. Its peptide structural determination and mass spectrometry analysis both provide evidence that the different peptide chains constituting ltl are associated by the new cross-link described as the protein-glycosaminoglycan-protein cross-link. [ABSTRACT FROM AUTHOR]

Published
1994
Full Text
View/download PDF

22. Groupe de travail SFBC « Marqueurs biochimiques de COVID-19 »

Author

Marie-Christine, Beauvieux, Annie M, Bérard, Isabelle, Aimone-Gastin, Françoise, Barbé, Yann, Barguil, Delphine, Collin-Chavagnac, Hervé, Delacour, Céline, Delevallée, Valérie, Nivet-Antoine, Katell, Peoc'h, Carole, Poupon, François, Schmitt, Laurence, Piéroni, Vincent, Sapin, Charlotte, Oris, CarMeN, laboratoire, CHU Bordeaux [Bordeaux], Centre de résonance magnétique des systèmes biologiques (CRMSB), Université de Bordeaux (UB)-Centre National de la Recherche Scientifique (CNRS), Université de Bordeaux (UB), Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre hospitalier territorial Gaston-Bourret [Nouméa], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Hôpital d'Instruction des Armées Begin, Service de Santé des Armées, Gen-Bio [Clermont-Ferrand] (Groupe Inovie ), Innovations thérapeutiques en hémostase (IThEM - U1140), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Beaujon, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Centre Hospitalier de Gonesse (CHU Gonesse), Groupe Hospitalier Bretagne Sud (GHBS), CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Génétique, Reproduction et Développement (GReD), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne (UCA), Membres du Groupe de travail SFBC « Marqueurs biochimiques de COVID-19 » Aimone-Gastin Isabelle, Alcaraz Stéphanie, Allouche Stéphane, Balduyck Malika, Barbé Franc¸oise, Barguil Yann, Bastard Jean-Philippe, Beaudeux Jean-Louis, Beauvieux Marie-Christine, Ben Lassoued Amin, Benz de Bretagne Isabelle, Bérard Annie, Bermont Laurent, Bigot-Corbel Edith, Bost Muriel, Bourbonneux Valery, Brunel Valery, Carré Jean-Luc, Chenevier-Gobeaux Camille, Chevrier Marc, Chinetti Giulia, Collin-Chavagnac Delphine, Delacour Hervé, Delevallée Delphine, Desroys du Roure Franc¸ois, Faure Patrice, Galhaud Jean-Philippe, Galinier Anne, Hauet Thierry, Hejl Carine, Jolly Emilie, Kamel Said, Lehmann Sylvain, Leroy Aline, Lessinger Jean-Marc, Levy Pacifique, LorecPenet Anne-Marie, Mesli Samir, Monnet Dagui, Moreau Caroline, Mouly Laurence, Nivet-Antoine Valérie, Oueidat Nathalie, Pecquet Mathieu, Peoc’h Katell, Piéroni Laurence, Poupon Carole, Roubille Martine, Rucheton Benoit, Sakka Medhi, Sapin Vincent, Saunier Vincent, Scherrer Florian, Schmitt Franc¸ois, Zaepfel Sabine, Zozor Samuel Liste des correspondants en biochimie Sous-groupe Privés Boulier Alexandre (Saint-Thibery), Saint Martin Chloé (Saint-Flour), Chatelain Rémi (Roanne), Deleglise Guillaume (Clermont-Ferrand), Froment Pauline (Ganges), Paulus Jean-Marcel (Nancy), Merah Kader (Saint-Denis), Sevin Eric (Limoges), Barrand Lionel (Strasbourg), Boetsch Morgane (Colmar), Lautier Carine (Montpellier), Charrier Frédéric (Arles), Magraff Stéphane (Brumath) Sous-groupe Outre-Mer (OM)/francophonie Cavalier Etienne (CHU Liège), Demar Magali (CH Cayenne), de Guire Vincent et Wang Han Ting (Montréal), Laso Bautista Javier (HFE Cerdagne), Dumas-Chastang Elsa (Papeete, ILM), Outreville Jonathan (Papeete, CHT Mamao), Tayeb Nicole (CH Mayotte), Monde Absalome (CHU Treichville Abidjan), Chiaradia Laura (CH Nouméa), Alomar Yves (CH de St Pierre & Miquelon), Devaud Francois (CH d’Uturoa), Diallo Agne Fatou, Kandji Pape Matar, Gueye Papa Madieye (CHU Fann, Sénégal), Temmar Abdelhakim (CHU de Guadeloupe), Sakandé Jean et Kabré Elie (CHU Yalgado Uuedraogo, Burkina Faso), Padelli Maël (CHU de Martinique), Chabraoui Layachi, pour la Fédération Internationale Francophone de Biologie et Médecine de Laboratoire (FIFBCML), Magny Eric (CHU Réunion) Sous-groupe CH Got Laurence et Francia Thomas (Orléans), Tournoys Marie-Hélène (Béthune), Morvan Cécile (Villefranche), Kadi Habiba (Gonesse), Balluet Rémi (Bourg-en-Bresse), Fissor-Magdelein Cristel (Monaco) Sous-groupe Hôpitaux d’instruction des armées (HIA) Vest Philippe (Clamart), Plantamura Julie (Toulon) Sous-groupe CHU Nord-Est Salignac Sylvain (Nancy), Maboudou Patrice et Onraed Brigitte (Lille), Schneider Nathalie et Szymezak Jean (Reims), Alemann Mathieu, Glady Ludovic, Lavaux Thomas, Kemmel Véronique, Lefevre Paul et Bayer Sophie (Strasbourg), Billoir Paul et Gueudin Marie (Rouen), Grandhomme Frédérique et Gondolf Clémentine (Caen) Sous-groupe CHU Ouest Moal Valérie et Larcher- Joubaud Franc¸oise (Angers), Guery Eve-Anne (Tours), Lefevre Charles, Collet Nicolas et Peltier Lucas (Rennes), Lacape Geneviève, Redonnet-Vernhet Isabelle, Richard Emmanuel et Gilleron Véronique (Bordeaux) Sous-groupe CHU Assistance publique-Hôpitaux de Paris (AP-HP) Czerkiewicz Isabelle (Henri Mondor), Vicca Stéphanie (Necker), Manceau Hanna (Beaujon), Boutten Anne (Bichat) Sous-groupe CHU Sud Ausseil Jérôme (Toulouse), Hamoir Maria, Zemori Laurence, Deconde-Lebutor Célia (Nice), Lamy Anaïs (Nîmes) Sous-groupe CHU Auvergne Rhône-Alpes-Bourgogne Franche-Comté (ARA-BFC) Gambert Ségolène (Dijon), Gonzalo Philippe (Saint-Etienne), Cartier Régine (Lyon), and Oris Charlotte (ClermontFerrand)

Subjects
030213 general clinical medicine, History, [SDV]Life Sciences [q-bio], Disease, France/epidemiology, Biochemistry, Community Networks, Disease Outbreaks, Viral/blood/*diagnosis/epidemiology, 0302 clinical medicine, Health care, Pandemic, Videoconferencing/organization & administration/standards, Intersectoral Collaboration, medical biology, Professional Practice, General Medicine, Clinical Laboratory Services, biological markers, 21st Century, 3. Good health, [SDV] Life Sciences [q-bio], France, Coronavirus Infections, Biomarkers/*analysis/blood, Societies, Scientific, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Pneumonia, Viral, Biochemistry/*organization & administration/standards, History, 21st Century, Scientific/*organization & administration/standards, 03 medical and health sciences, Betacoronavirus, Community Networks/organization & administration/standards/trends, medicine, Clinical Laboratory Services/*organization & administration/standards, Humans, Betacoronavirus/isolation & purification/pathogenicity, Medical prescription, China, Pandemics, Professional Practice/organization & administration/standards/trends, business.industry, SARS-CoV-2, COVID-19, Pneumonia, Private sector, Family medicine, covid-19, Coronavirus Infections/blood/*diagnosis/epidemiology, Videoconferencing, business, Societies, Biomarkers
Abstract

The SARS-CoV-2 virus is responsible for an epidemic disease called COVID-19, which was initially evidenced in Wuhan, China, and spread very rapidly in China and around the world. In France, the first isolated case seems now to be reported in December 2019, stage 3 of the COVID-19 epidemic was triggered on March 14(th), the start of the planned containment exit from May 11(th). Healthcare services have faced a large influx of patients who may be beyond their capacity to receive and care, particularly in the Large-East and Ile-de-France regions. Some patients show an evolution of the disease never observed before with other coronaviruses and develop in a few days a very important inflammatory reaction, which can lead to death of patients. A working group of the French Society of Clinical Biology (SFBC) was set up with the objective of providing updated information on the current status of the biological prescriptions (focusing on biochemistry ones) and their evolution during the epidemic, and of analyzing the biological parameters associated with comorbidities and patient evolution in order to link biological results with medical events. The expanded working group covers all sectors of medical biology in France and extends to the French-speaking world: hospital sectors (CHU and CH, Army Training Hospitals) and the private sector opening a field of view on the biological situation in establishments for dependent elderly, social establishments and clinical medical institutions. The purpose of this article is the presentation of this working group and its immediate and future actions., Le virus SARS-CoV-2 est responsable d’une maladie épidémique dénommée COVID-19 initialement mise en évidence à Wuhan (Chine) et qui s’est propagée très rapidement en Chine puis dans le monde entier. En France, le premier cas isolé semble être signalé dès la fin du mois de décembre2019, le stade 3 de l’épidémie a été déclenché le 14 mars 2020 et la sortie progressive du confinement est prévue à partir du 11 mai 2020. Les services de soins ont fait face à un afflux massif de patients pouvant déborder leurs capacités d’accueil et de prise en charge, notamment dans les régions Grand-Est et Ile-de-France. Certains patients présentent une évolution de la maladie encore jamais observée avec les coronavirus et développent en quelques jours une réaction inflammatoire très importante, pouvant mener au décès. Un groupe de travail de la Société française de biologie clinique (SFBC) s’est constitué, ayant pour objectif de faire le point sur les prescriptions biologiques et leur évolution au cours de l’épidémie, d’analyser les paramètres biologiques, avec un focus biochimique, associés aux comorbidités et à l’évolution du patient, dans le but de relier les résultats biologiques avec des évènements du parcours de soins du patient. Ce groupe de travail recouvre tous les secteurs publics (CHU, CH, Hôpitaux d’instruction des armées) et privés de la biologie médicale en France métropolitaine et ultra-marine ; il s’étend également à la francophonie. Il permet une vision large sur la situation biologique en milieu hospitalier, établissements d’hébergements de personnes âgées dépendantes (Ehpad), établissements médicaux sociaux (EMS) et en cliniques. Le but de cet article est la présentation de ce groupe de travail et ses actions immédiates et à venir.

Published
2020

23. Performance of the BODE index in patients with α1-antitrypsin deficiency-related COPD.

Author

Thabut G, Mornex JF, Pison C, Cuvelier A, Balduyck M, Pujazon MC, Fournier M, AitIlalne B, and Porcher R

Subjects
Adult, Aged, Area Under Curve, Calibration, Emphysema complications, Emphysema diagnosis, Emphysema mortality, Female, France, Humans, Lung Transplantation, Male, Middle Aged, Probability, Prognosis, Prospective Studies, Pulmonary Disease, Chronic Obstructive mortality, ROC Curve, Software, Treatment Outcome, alpha 1-Antitrypsin Deficiency mortality, Pulmonary Disease, Chronic Obstructive complications, Pulmonary Disease, Chronic Obstructive diagnosis, Severity of Illness Index, alpha 1-Antitrypsin Deficiency complications, alpha 1-Antitrypsin Deficiency diagnosis
Abstract

The BODE (body mass index, airflow obstruction, dyspnoea and exercise capacity) index is used to decide on referral and transplantation of patients with chronic obstructive pulmonary disease (COPD). The BODE index has not been validated in patients with α1-antitrypsin deficiency, who account for 15% of COPD patients undergoing lung transplantation. We sought to validate the BODE index in α1-antitrypsin deficiency-related COPD. We assessed the prognostic value of the BODE index in 191 patients followed from 2006 to 2012 in a French prospective cohort of patients with α1-antitrypsin deficiency. 20 patients died during follow-up and 22 underwent lung transplantation. Survival (95% CI) was 93.0% (91.7-94.3%) at 3 years and 76.0% (72.9-79.1%) at 5 years. The 3-year survival was 97.4% (96.6-98.2%), 98.0% (96.7-99.3%), 87.7% (84.5-90.9%) and 75.3% (66.0-84.6%) for patients with BODE index 0-2, 3-4, 5-6 and 7-10, respectively. Survival discrimination of the BODE index was better than with both forced expiratory volume in 1 s and Global Initiative for Chronic Obstructive Lung Disease classification. Regarding calibration, expected survival by BODE index was noticeably lower than observed survival. The BODE index showed very good survival discrimination in patients with α1-antitrypsin deficiency-related COPD. Larger studies are needed to support its use to drive patient referral for lung transplantation., (©ERS 2014.)

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results